Resistance to Hypomethylating Agents in Myelodysplastic Syndrome and Acute Myeloid Leukemia From Clinical Data and Molecular Mechanism

The nucleoside analogs decitabine (5-AZA-dC) and azacitidine (5-AZA) have been developed as targeted therapies to reverse DNA methylation in different cancer types, and they significantly improve the survival of patients who are not suitable for traditional intensive chemotherapies or other treatmen...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhao, Guangjie, Wang, Qian, Li, Shuang, Wang, Xiaoqin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2021
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8505973/
https://www.ncbi.nlm.nih.gov/pubmed/34650913
http://dx.doi.org/10.3389/fonc.2021.706030

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8505973/
https://www.ncbi.nlm.nih.gov/pubmed/34650913
http://dx.doi.org/10.3389/fonc.2021.706030

Ejemplares similares